<SEC-DOCUMENT>0001213900-24-053908.txt : 20240827
<SEC-HEADER>0001213900-24-053908.hdr.sgml : 20240827
<ACCEPTANCE-DATETIME>20240618183055
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-24-053908
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD>
  <TD STYLE="width: 30%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Wilson Sonsini Goodrich &amp; Rosati<BR>
Professional Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">650 Page Mill Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Palo Alto, California 94304-1050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">o</FONT>: 650.493.9300<BR>
<FONT STYLE="font-variant: small-caps">f</FONT>: 866.974.7329</P>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Via EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549-3628</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Ibolya Ignat, Daniel Gordon, Tamika Sheppard and Joshua
Gorsky</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>Re:</B></TD><TD STYLE="text-align: justify"><B>ARCA biopharma, Inc.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in"><B>Registration Statement on Form S-4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in"><B>Filed May 14, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in"><B>File No. 333-279387</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of ARCA biopharma, Inc. (the &ldquo;<U>Company</U>&rdquo;),
we are submitting this letter to the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) via EDGAR in response to the comment
letter from the staff of the SEC (the &ldquo;<U>Staff</U>&rdquo;), dated June 11, 2024 (the &ldquo;<U>Comment Letter</U>&rdquo;), pertaining
to the Company&rsquo;s above-referenced Registration Statement on Form S-4 (the &ldquo;<U>Registration Statement</U>&rdquo;). In connection
with such responses, the Company is concurrently filing Amendment No. 1 to the Registration Statement (the &ldquo;<U>Amended Registration
Statement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For your convenience, the Staff&rsquo;s comments
are summarized in this letter, and each comment is followed by the applicable responses on behalf of the Company. Unless otherwise indicated,
page references in the responses correspond to the page numbers in the Amended Registration Statement. Capitalized terms used in this
letter but otherwise not defined herein shall have the meanings set forth in the Amended Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Registration Statement on Form S-4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cover Page</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><I>Please clarify your disclosure to state, if true, that upon the completion of the proposed merger,
the combined company will be a &ldquo;controlled company&rdquo; under the Nasdaq listing rules. To the extent necessary, please also add
a risk factor discussing the risks to shareholders related to owning shares in a controlled company.</I></TD></TR>
                                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on the Cover
Page of the Amended Registration Statement in response to the Staff&rsquo;s comment to state that the Company will not be a &ldquo;controlled
company&rdquo; under the Nasdaq listing rules. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><I>We note your disclosure that ARCA &ldquo;intends to file an initial listing application for the combined
company with Nasdaq.&rdquo; Please revise your disclosure here to clarify whether the Merger is contingent upon the approval of your Nasdaq
listing application.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on the Cover
Page and on page 13 of the Amended Registration Statement in response to the Staff&rsquo;s comment to state that the listing approval
for ARCA biopharma, Inc.&rsquo;s securities on the Nasdaq is a closing condition of the merger. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">austin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;beijing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BOULDER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brussels&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;hong kong&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;london&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;los angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;new york&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;palo alto<BR>
SALT LAKE CITY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;san diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;san francisco&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;seattle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shanghai&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;washington, dc&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;wilmington, de</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risk Factors</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risks Related to the Merger</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>ARCA&rsquo;s expected disposal of its
historical assets and operations in connection with its proposed Merger&hellip;, page 15</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><I>We note your disclosure here that &ldquo;ARCA has two remaining ongoing development programs, and it
will dispose of (or is in the process of disposing of) its legacy technology and intellectual property.&rdquo; Please clarify here and
elsewhere as appropriate whether ARCA expects to dispose of its historical assets regardless of whether the stockholders approve the Merger.
Additionally, please clarify here and elsewhere as appropriate whether the &ldquo;legacy technology and intellectual property&rdquo; that
ARCA is in the process of disposing of includes the development programs for Gencaro and rNAPc2.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 18
and 198 of the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risks Related to Oruka&rsquo;s Reliance
on Third Parties</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Oruka currently relies, and plans to rely
in the future, on third parties&hellip;, page 72</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><I>Please revise your disclosure to explain that the current U.S. House of Representatives version
of the BIOSECURE Act identifies WuXi Biologics as a biotechnology company of concern. Additionally, please revise your disclosure to clarify&nbsp;whether
WuXi Biologics (Hong Kong) Limited is a subsidiary or affiliate of WuXi Biologics.&nbsp;</I></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page 73 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The Merger</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Background of the Merger, page 96</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><I>We note your disclosure that in June of 2022, the Special Committee determined to abandon a non-binding
proposal for a reverse merger styled transaction due to the counterparty&rsquo;s &ldquo;early stage of development and substantial cash needs.&rdquo;
Please revise your disclosure here to provide further details about that counterparty&rsquo;s stage of development.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page 98 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><I>We note your disclosure that it was the view of the Special Committee &ldquo;that the $6,000,000 enterprise
value ascribed to ARCA was within the range of values ascribed in other recent reverse merger transactions . . . .&rdquo;&nbsp;Please provide
further details about the range of values that the Special Committee examined in this regard, including, but not limited to, the low-end
and high-end of those values. Additionally, please provide further details about the companies that were involved in the other recent
reverse merger transactions that the Special Committee reviewed.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 102,
115, 116, 118, 119 and 120 of the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Material U.S. Federal Income Tax Consequences
of the Merger, page 125</U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><I>We note your disclosure that the parties &ldquo;intend&rdquo; for the Merger&nbsp;to qualify as a reorganization
within the meaning of Section 368(a) of the Internal Revenue Code. Please revise to make clear whether the parties expect the Merger&nbsp;to
be tax-free to U.S. holders. If you are able to conclude that the Merger&nbsp;is likely to be tax-free to U.S. holders, please file a
tax opinion supporting such a conclusion.&nbsp;If there is uncertainty regarding the tax treatment of the Merger, counsel&rsquo;s opinion
should discuss the degree of uncertainty.&nbsp;For further guidance see Staff Legal Bulletin No. 19 and Item 601(b)(8) of Regulation S-K.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that, in accordance with Section III of Staff Legal
Bulletin No. 19, the Company will file a pre-effective amendment that includes opinions of counsel from the Company and Oruka covering
the material tax consequences of the merger as Exhibit 8.1 and Exhibit 8.2 to the Registration Statement and will revise the applicable
disclosures in the Registration Statement accordingly. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>ARCA&rsquo;s Business</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Overview, page 196</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><I>We note your disclosure on page 18&nbsp;that ARCA plans to dispose of its historical assets and operations
in connection with the proposed Merger. Please revise your disclosure in this section and elsewhere as appropriate to explain how and
when&nbsp;the disposal of such assets and operations is expected to take place.&nbsp;</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 18 and 198 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>ORKA-001, page 212</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><I>We note your disclosure that &ldquo;[b]ased on recent precedent for PsO, Oruka anticipates that the
entire development program from first-in-human to biologics license application [] filing could take as little as six to seven years based
on the averages for recently approved medicines.&rdquo; Please revise your disclosure here to note that Oruka has no control over the length
of time needed for FDA review.&nbsp;</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page 215 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Oruka&rsquo;s Business</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Overview, page 212</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><I>We note your disclosure on page 73 that Oruka currently relies on foreign CROs and CMOs, &ldquo;including
WuXi Biologics (Hong Kong) Limited [&nbsp;&nbsp;] and will likely continue to rely on foreign CROs and CMOs in the future.&rdquo; Please revise your
disclosure in this section to disclose the nature of the business that Oruka conducts with WuXi Biologics (Hong Kong) Limited.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page 73 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Oruka&rsquo;s Pipeline, page 212</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><I>Please revise your disclosure to explain what is meant by the term &ldquo;Combinations&rdquo; as it appears
in the pipeline table.&nbsp;</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page 214 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Clinical Development Plans, page 223</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>12.</B></TD><TD STYLE="text-align: justify"><B><I>Please clarify whether Oruka has submitted an IND with the FDA for Phase 1 clinical trials involving either ORKA-001 or ORKA-002.&nbsp;</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 225
and 226 of the Amended Registration Statement in response to the Staff&rsquo;s comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal"><IMG SRC="image_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Management Following the Merger</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Non-Employee Directors, page 272</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><I>Please revise your disclosure here with respect to Ms. Ball to specifically identify the experience,
qualifications, attributes or skills that led to the conclusion that Ms. Ball should serve as a director. Refer to Item 401(e) of Regulation
S-K.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 274 and 275 of
the Amended Registration Statement in response to the Staff&rsquo;s comment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Unaudited Pro Forma Condensed Combined
Financial Information</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Notes to Unaudited Pro Forma Condensed
Combined Financial Information</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Accounting for the Merger, page 289</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">14.</TD><TD STYLE="text-align: justify"><I>Please&nbsp;provide us an analysis concerning whether ARCA will become a&nbsp;shell&nbsp;company as
defined in Rule 12b-2&nbsp;of the Exchange Act&nbsp;prior to the closing of the Merger.&nbsp; Explain the plans for ARCA&rsquo;s two remaining
ongoing development programs.&nbsp;Revise your disclosures as necessary to support the reverse recapitalization accounting planned for
the Merger.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><U>Response</U>: Rule 12b-2 of the
Exchange Act defines a shell company as &ldquo;a registrant &hellip; that has: (1) No or nominal operations; and (2) Either: (i) No or
nominal assets; (ii) Assets consisting solely of cash and cash equivalents; or (iii) Assets consisting of any amount of cash and cash
equivalents and nominal other assets. The test for a shell company is conjunctive; that is, it must satisfy both prongs of the definition
in order to qualify as a shell company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">With respect to prong (1), the Company
during the three months ended March 31, 2024 had ongoing operations as reflected in its quarterly spend of $2.4 million, a portion of
which related to research and development expenses. As such, the Company has more than nominal operations. With respect to prong (2),
the Company has two remaining ongoing development programs, Gencaro and rNAPc2, including technology and intellectual property related
to such programs. As such, the Company has more than nominal other assets. In the absence of the Merger, the Company would not consider
itself a shell company and, accordingly, prior to the consummation of the Merger, the Company will not consider itself a shell company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In January of 2024, the SEC published
an adopting release with respect to Special Purpose Acquisition Companies, Shell Companies, and Projections (the &ldquo;<U>Release</U>&rdquo;).
In footnote 943 of the Release, the SEC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">clarified what it has stated to have
been its longstanding position that &ldquo;the requirements applicable to reporting shell company business combinations adopted herein
will apply to any company that sells or otherwise disposes of its historical assets or operations in connection with or as part of a plan
to combine with a non-shell private company in order to convert the private company into a public one. This is true regardless of whether
such sale or disposal of the legacy assets or operations occurs prior to or after the consummation of the business combination.&rdquo;
As reflected, in the Amended Registration Statement, the Company expects to dispose of its legacy technology and intellectual property,
including those related to Gencaro and rNAPc2, upon the consummation of the Merger. Any such disposal of legacy technology and intellectual
property will be contingent upon obtaining stockholder approval for the Merger. Accordingly, the Company acknowledges that in accordance
with the SEC&rsquo;s position articulated in the Release, the Company will become a shell company upon consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">With
respect to the reverse recapitalization accounting treatment that is reflected in the Unaudited Pro Forma Condensed Combined Financial
Information, the Company is considered in the Merger to be the accounting acquirer. According to section 12100 of the SEC&rsquo;s Financial
Reporting Manual, &ldquo;[t]he Staff considers a public shell reverse acquisition to be a capital transaction in substance, rather than
a business combination. That is, the transaction is a reverse recapitalization, equivalent to the issuance of stock by the private company
for the net monetary assets of the shell corporation accompanied by a recapitalization. The accounting is similar to that resulting from
a reverse acquisition, except that no goodwill or other intangible assets should be recorded.&rdquo; Given the Company&rsquo;s conclusion
above that the Company will become a shell company upon consummation of the Merger, we respectfully note our view that the accounting
treatment that is reflected in the Unaudited Pro Forma Condensed Combined Financial Information is accurate as written.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Adjustments to Unaudited Pro Forma Condensed
Combined Balance Sheet as of March 31, 2024, page 290</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><I>Please revise your disclosure in this note to more clearly explain how you arrived to the amounts
presented&nbsp;for adjustment 5(c.)&nbsp;For example, it is not clear from your narrative whether the $249.8 million adjustment to
cash is&nbsp;net of transaction costs of&nbsp;$20.0&nbsp;million given that&nbsp;the transaction costs appear to have been accounted
for on a separate line through adjustment 5(d.) Consider disaggregating the $249.8 million adjustments recorded to cash and to APIC
similar to the table presented for adjustment 5(j.)</I></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page 292 of
the Amended Registration Statement in response to the Staff&rsquo;s comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Comparison of Rights of Holders of ARCA
Capital Stock and Oruka Capital Stock, page 299</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify"><I>We note your disclosure here, as well as in your risk factor on page 84 that the combined company will
provide for the federal district courts of the United States of America to&nbsp;be the exclusive forum for the resolution of any complaint
asserting a cause of action against the combined company or any of its directors, officers, employees, or agents and arising under the
Securities Act.&nbsp;Please disclose that there is uncertainty as to whether a court would enforce such a provision. Please also state
that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. In that regard, we note
that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any
duty or liability created by the Securities Act or the rules and regulations thereunder. Additionally, please revise to note that this
provision may also make it more costly for a shareholder to bring a claim against you.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 85 and
310 of the Amended Registration Statement in response to the Staff&rsquo;s comment. The Company respectfully notes that Oruka&rsquo;s
current charter and bylaws do not contain a federal exclusive forum clause and that Oruka&rsquo;s current charter and bylaws will not
be applicable post-closing because Oruka will become a subsidiary of the Company upon completion of the First Merger. With respect to
the comment to state that investors cannot waive compliance with the federal securities laws, the Company respectfully notes that this
is already addressed in the risk factor on page 85 of the Amended Registration Statement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Principal Stockholders of ARCA, page 309</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify">For the table here, as well as the table on page 312, please identify in&nbsp;footnotes all natural persons
who have voting and/or investment power over the shares held by named entities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-weight: normal"><U>Response</U>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 313
and 316 of the Amended Registration Statement in response to the Staff&rsquo;s comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">*****</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please contact the undersigned at (303) 256-5901
or via email at bfassett@wsgr.com if you have any questions with respect to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Brent D. Fassett</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Brent D. Fassett</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Wilson Sonsini Goodrich &amp; Rosati P.C.</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">cc:</TD><TD STYLE="text-align: justify">Thomas A Keuer, <I>ARCA biopharma, Inc.</I></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">C. Jeffrey Dekker, <I>ARCA biopharma, Inc.</I></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Ethan Lutske, <I>Wilson Sonsini
Goodrich &amp; Rosati P.C. </I></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Ross Tanaka, <I>Wilson Sonsini
Goodrich &amp; Rosati P.C.</I></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Savir S. Punia, <I>Wilson
Sonsini Goodrich &amp; Rosati P.C.</I></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Ryan A. Murr, <I>Gibson,
Dunn &amp; Crutcher LLP</I></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Branden C. Berns, <I>Gibson,
Dunn &amp; Crutcher LLP</I></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P ( # 2(  A$! Q$!_\0
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ME_9$@6L3 _(/7G.#VP#BN>USX7:/XAO[C5O#6KBRO1*PD$+;HQ*#ST.4.?\
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MFE7-_+?LN_=/)E68,2<=2>,XZU2\%>-K'QIILEQ;(8+B%MLUNS;F3T.>X/\
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GD;S$(P0R\9K7^.UM/<1:)Y$$DN&FSL0MC[GI3_Y>(G5X=^OZG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 $ # 2(  A$! Q$!_\0
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C9]<@"J:F:X^!.KR/ \<LM[(YBP<J3*IQ1133_0EP2N_4_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
